GENVIVO
GenVivo creates novel gene therapies to treat cancer, extend patient survival, and improve quality of life. Their approach to killing tumors while activating the immune system to fight the patient's cancer, combined with the incorporation of novel companion diagnostics, places us at the forefront of cancer immunotherapies and emerging clinical-stage cancer companies.
GENVIVO
Social Links:
Industry:
Biotechnology Health Care Medical
Address:
San Marino, California, United States
Country:
United States
Website Url:
http://www.genvivoinc.com
Total Employee:
11+
Status:
Active
Contact:
+1 626 441 6695
Official Site Inspections
http://www.genvivoinc.com
- Host name: 10.0.153.160.host.secureserver.net
- IP address: 160.153.0.10
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "GenVivo"
Gene Therapy Company | Discover GenVivo's Innovative Solutions
The Research & Development Department consists of a dedicated team of scientists. Our combined experience covers a diverse range of backgrounds including: gene therapy using …See details»
Gene Therapy for Cancer | Revolutionary Treatment Options
Our Organization; Platform; Pipeline; News. Publications; Press Releases; Careers; Contact. text. About Us company photo summer 2024. Who We Are At GenVivo, fighting cancer is more …See details»
GenVivo, Inc. - LinkedIn
GenVivo, Inc. | 535 followers on LinkedIn. We are a clinical stage company with an off-the-shelf, vector-based platform, for immunotherapeutics in oncology | GenVivo was founded on the idea that ...See details»
GenVivo Company Profile | Management and Employees List
[email protected]: GenVivo Top Competitors. Company Employees Revenue Top technologies; ProMab Biotechnologies Inc. 27: $8.3 M: ExonBIO. 17: $4.7 M: Syd Labs Inc. …See details»
GenVivo - Crunchbase Company Profile & Funding
GEN2: GEN2 is a non-replicating mRNA gene therapy vector designed to kill tumors and activate the patient's immune system against cancer antigens, currently in Phase 1 clinical trials.See details»
GENVIVO, INC. Company Profile | San Marino, CA | Competitors ...
Find company research, competitor information, contact details & financial data for GENVIVO, INC. of San Marino, CA. Get the latest business insights from Dun & Bradstreet.See details»
Genvivo Incorporated - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Genvivo Incorporated of Ontario, CA. Get the latest business insights from Dun & Bradstreet.See details»
GenVivo - Overview, News & Similar companies | ZoomInfo.com
GenVivo contact info: Phone number: (626) 441-6695 Website: www.genvivoinc.com What does GenVivo do? GenVivo is a Biotechnology company in San Marino, California, that develops …See details»
GenVivo, Inc. Careers and Employment | Indeed.com
Jun 10, 2023 Find out what works well at GenVivo, Inc. from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular …See details»
Leadership - GenVivo
Dr. Roh received her B.S. in Chemistry from Boston College and her M.A. and Ph.D. in Biochemistry from Boston University School of Medicine. She then completed her postdoctoral …See details»
GenVivo to Present at the 2023 American Society of Gene and Cell ...
May 19, 2023 [email protected]. You just read: GenVivo to Present at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. News Provided By. …See details»
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing …
PASADENA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- GenVivo, Inc. (GVO) a private, clinical stage biopharmaceutical company with breakthrough “off-the-shelf” gene vector …See details»
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib ...
Jun 27, 2024 GEN2’s dose-escalation trial, GVO-1102, will establish the Recommended Phase 2 Dose (RP2D), followed immediately by an expansion phase into 3 solid tumor types.GEN2 …See details»
Platform - GenVivo
GenVivo’s platform has been engineered to overcome key challenges of past vector-based immunotherapy approaches. Our non-replicating retrovector-based platform is designed to …See details»
Working at GenVivo - Glassdoor
30 min. phone screening with project manager, thenone week later had 2 hour zoom meeting (due to Covid restrictions) with 30 min. sessions each with project scientists, research scientists, …See details»
GenVivo to Present Phase 1 Trial Results for GEN2, A
Nov 8, 2024 GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingSee details»
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing …
Nov 8, 2024 GEN2 was studied in patients with hepatocellular carcinoma or advanced solid tumors metastatic to the liver and was well-tolerated at all dose levels administered 21% of …See details»
GenVivo to Present Phase 1 Trial Results for GEN2, A ... - Morningstar
Nov 8, 2024 Contact Victor Constantinescu Head of Business Development [email protected] 626-768-5162. More in Markets View All. Healthcare Stocks Got …See details»
Advances in Cancer Research | Revolutionizing Cancer Treatment
Our lead candidate, GEN2, carries a proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Granulocyte …See details»